Carlsmed (NASDAQ:CARL) COO Jeffrey Bertolini Sells 747 Shares of Company Stock

Carlsmed, Inc. (NASDAQ:CARL) COO Jeffrey Bertolini sold 747 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $15.15, for a total transaction of $11,317.05. Following the transaction, the chief operating officer directly owned 22,489 shares in the company, valued at $340,708.35. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jeffrey Bertolini also recently made the following trade(s):

• On Friday, October 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $15.80, for a total transaction of $3,839.40.
• On Monday, October 5th, Jeffrey Bertolini sold 747 shares of Carlsmed stock. The shares were sold at an average price of $14.39, for a total transaction of $10,749.33.
• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $13.99, for a total transaction of $3,399.57.

Carlsmed Price Performance

Shares of NASDAQ:CARL opened at $16.09 on Thursday. Carlsmed, Inc. has a one year low of $8.50 and a one year high of $17.23. The company has a 50-day simple moving average of $14.98 and a 200-day simple moving average of $12.47. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $18.94 million for the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. As a group, equities research analysts forecast that Carlsmed, Inc. will post -1.50 EPS for the current year.

Institutional Investors Weigh In On Carlsmed

Hedge funds have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new position in shares of Carlsmed during the 2nd quarter worth approximately $12,992,000. Janus Henderson Group PLC lifted its holdings in shares of Carlsmed by 7.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock valued at $11,108,000 after buying an additional 86,834 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of Carlsmed in the 2nd quarter valued at approximately $6,200,000. BlackRock Inc. purchased a new stake in shares of Carlsmed in the second quarter valued at approximately $5,528,000. Finally, KCM Capital Inc purchased a new stake in shares of Carlsmed in the first quarter valued at approximately $1,810,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CARL. BTIG Research lifted their target price on Carlsmed from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Weiss Ratings upgraded Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Truist Financial increased their price target on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.